Autor: Firma Cardior Pharmaceuticals

Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior’s First-in-Class Heart Failure Program

29. März 2021 Firma Cardior PharmaceuticalsAllgemeinantisense, cardiomyocytes, cardior, cdr132l, clinical, dosing, hypertrophy, MICE, mirna, patients, research, rna, switch, therapy, with

Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that a recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. Mehr

Cardior Pharmaceuticals‘ Lead Compound Demonstrates Improvement of Heart Function in Chronic Heart Failure Model

22. Oktober 2020 Firma Cardior PharmaceuticalsMedizintechnikatrial, cardiomyocytes, cardior, clinical, cmri, dosing, endpoint, hypertrophy, injection, patients, research, rna, switch, treatment, with

Safety and efficacy of CDR132L established in an in vivo model of chronic post-MI heart failure Study by international research team published in European Heart Journal Broad treatment potential for chronic heart failure Cardior Pharmaceuticals GmbH, a clinical-stage biotech company, Mehr

Cardior Pharmaceuticals Demonstrates Reversal of Cardiac Hypertrophy by H19 Gene Therapy

13. Juli 2020 Firma Cardior PharmaceuticalsMedizintechnikcardiac, cardior, cells, clinical, hypertrophy, lncrna, medical, MICE, new, nfat, patients, research, rna, therapy, with

Administration of AAV9 expressing H19 attenuates cardiac hypertrophy in vivo and prevents progression to heart failure Details on novel mechanism of action published in peer-reviewed study in the European Heart Journal Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on Mehr